Skip to main content
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. logo

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. — Investor Relations & Filings

Ticker · 2395 ISIN · JP3379950003 LEI · 529900C10QR47J2U5R44 T Professional, scientific and technical activities
Open in API
Filings indexed 65 across all filing types
Latest filing 2025-11-07 Regulatory Filings
Country JP Japan
Listing T 2395

About SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

https://en.snbl.com/

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a contract research organization (CRO) providing comprehensive drug development services. Established in 1957 as Japan's first CRO, the company supports pharmaceutical clients throughout the development lifecycle, from preclinical safety studies to clinical trial management. SNBL offers a full suite of services, including safety assessments and clinical data management. A key area of innovation is its proprietary nasal drug delivery technology, SMART (Simple MucoAdhesive Release Technology). The company's mission is to contribute to medical advancement and alleviate patient suffering by supporting the creation of new pharmaceuticals.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references '金融商品取引法第24条の５の２第１項' (Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification confirming the accuracy of the contents of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (in this case, a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 53
2025-11-07 Japanese
半期報告書－第53期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Shin Nippon Biomedical Laboratories, Ltd. in Japan. It contains detailed financial statements, management analysis (MDA), and business performance metrics for the interim period (April 1, 2025, to September 30, 2025). This document is a formal regulatory filing required under the Financial Instruments and Exchange Act of Japan, which corresponds to the 'Interim / Quarterly Report' category in the provided schema. H1 2026
2025-11-07 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being filed because resolutions were passed at the Annual General Meeting (定時株主総会) held on June 27, 2025, pursuant to Japanese financial regulations (FSA Order Article 19, Paragraph 2, Item 9-2). Section 2 details the resolutions, which include the election of directors and the revision of director compensation. This structure—reporting the results of a shareholder meeting (specifically the AGM) immediately after it occurs—is characteristic of reporting the outcome of the Annual General Meeting. Since the content is the official results and details of the AGM resolutions, the most appropriate classification is AGM Information (AGM-R). It is not a general proxy solicitation (PSI) or a general regulatory filing (RNS), as it is highly specific to the AGM outcome.
2025-06-30 Japanese
確認書
Audit Report / Information Classification · 1% confidence The document text contains the header "有価証券報告書（通常方式）" which translates to "Securities Report (Regular Method)". It also explicitly mentions the submission to the Kanto Local Finance Bureau Director ("関東財務局長") based on Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act ("金融商品取引法第24条の４の２第１項"). Furthermore, it includes a confirmation statement by the representative director regarding the appropriateness of the contents of the "第52期...有価証券報告書" (52nd period Securities Report). In the US context, a comprehensive annual report filed under the Exchange Act is typically a 10-K. In the Japanese context, the 'Yuka Shoken Hokokusho' (Securities Report) serves the equivalent function of an annual financial disclosure document, which aligns best with the definition of the Annual Report (10-K) in this classification scheme, as it is the full yearly report covering performance, even if the specific Japanese filing code is different. Given the comprehensive nature implied by the title and content structure, 10-K is the most appropriate mapping. FY 2025
2025-06-27 Japanese
内部統制報告書－第52期(2024/04/01－2025/03/31)
Governance Information Classification · 1% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly references the legal basis as "金融商品取引法第24条の４の４第１項" (Financial Instruments and Exchange Act Article 24-4-4, Paragraph 1). This structure and content—detailing the framework, scope, criteria, and conclusion regarding the effectiveness of internal controls over financial reporting as of a specific fiscal year-end (March 31, 2025)—is characteristic of a formal internal control report filed in Japan, often accompanying the annual securities report (like a 10-K equivalent). While the Japanese filing system has specific forms, the content directly addresses the internal control assessment required annually. Given the provided options, this document is a comprehensive report detailing internal control findings, which aligns best with the scope of an Audit Report/Information (AR) or a comprehensive annual filing component. Since it is a standalone report on internal controls rather than the full annual report (10-K) or a simple announcement, and it contains detailed assessment criteria, 'AR' (Audit Report / Information) is the most appropriate fit among the choices for a detailed, non-annual-report financial assurance document.
2025-06-27 Japanese
有価証券報告書－第52期(2024/04/01－2025/03/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains the standard cover page with the filing date (2025-06-27), the fiscal year (2024-04-01 to 2025-03-31), and the company name (Shin Nippon Biomedical Laboratories, Ltd.). The document includes extensive XBRL tagging and financial data, confirming it is the full annual report rather than an announcement or summary. FY 2025
2025-06-27 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.